Clinical research
Only a week after Pfizer and BioNTech’s preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, Moderna reported interim efficacy data for its vaccine of 94.5%.
On Friday, the Boston-based company presented positive Phase III data in progressive familial intrahepatic cholestasis (PFIC) at the American Association for the Study of Liver Diseases’ annual meeting.
Late Friday, the regulatory agency rejected the medication of sutimlimab due to deficiencies from a pre-license inspection of a third-party manufacturing facility.
Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.
It was a particularly busy week for clinical trial updates, mostly because of several virtual conferences, including the virtual American Heart Association Scientific Sessions 2020 and The Society for Immunotherapy of Cancer’s Annual Meetings. Here’s a look.
AstraZeneca reported that the CALAVI Phase II trials of Calquence (acalabrutinib) in hospitalized patients with respiratory symptoms of COVID-19 failed to meet the trials’ primary efficacy endpoint.
Five Prime Therapeutics Inc., in collaboration Zai Lab Limited on the development bemarituzumab, a novel therapy for front-line advanced non HER2+ gastric or gastroesophageal junction (GEJ) cancer, on Wednesday announced groundbreaking positive topline Phase II results.
Pfizer announced today that it has received positive top-line results from the Phase III JADE REGIMEN study, examining abrocitinib for the treatment of severe atopic dermatitis.
Moderna released interim data from the expansion cohort of its ongoing Phase I trial of its mRNA personalized cancer vaccine, mRNA-4157.
Here’s a look at recent clinical trial pauses around the biopharma industry.
PRESS RELEASES